about
Searching for the human genetic factors standing in the way of universally effective vaccinesThe use of systems biology and immunological big data to guide vaccine development.Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine.Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine.Gene expression profiles are different in venous and capillary blood: Implications for vaccine studies.Non-specific immunological effects of selected routine childhood immunisations: systematic reviewHigh-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine.Characterizing vaccine responses using host genomic and transcriptomic analysis.The Clinical Application of MicroRNAs in Infectious DiseaseThe effect of chronic cytomegalovirus infection on pneumococcal vaccine responses.The B-cell response to a primary and booster course of MenACWY-CRM₁₉₇ vaccine administered at 2, 4 and 12 months of age.Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis Serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United KinA naturally protective epitope of limited variability as an influenza vaccine targetElevated risk of invasive group A streptococcal disease and host genetic variation in the human leukocyte antigen locusComparative transcriptomics between species attributes reactogenicity pathways induced by the capsular group B meningococcal vaccine, 4CMenB, to the membrane-bound endotoxin of its outer membrane vesicle componentCommon Genetic Variations Associated with the Persistence of Immunity following Childhood ImmunizationElevated risk of invasive group A streptococcal disease and host genetic variation in the human leucocyte antigen locus
P50
Q27007034-3052C5BD-F9F9-4714-AE27-E462F5FB6271Q31020862-1F08431F-C485-4167-ABDC-9F2F0CBCB677Q35157950-A2F71C5F-BAC3-4E66-AD88-D29610297F9EQ35805284-D1308FBA-57A9-4858-9E81-2D9BDB2AB28DQ36136877-9A63B4E8-8643-499D-B7E4-5EC3D4B827D2Q36163229-5CF9847C-BF58-43EF-B3E8-07B491BB82B5Q36264198-D11142FE-1270-4BB3-A2E0-03E7311623C1Q38111212-09D2C550-E950-471A-8479-13FBABFB92DFQ41921194-C79CE6E5-846B-49EA-A166-0986BEAD39F8Q45099647-CFC6BEF0-4BD6-4CAF-8B34-E09D971EA636Q50905949-84C1471D-F334-4785-B71D-B731B2A1B96CQ50907461-76BEECBC-A15E-4C41-B3AE-4383647E5951Q58382349-8CE34081-7ABB-4277-88EF-607AA8A6800DQ64134158-A72A0BF7-C2F6-40F8-A3C5-33ADC09A9BF9Q90262436-D1768075-8D82-49F0-BA48-5475B4556629Q92685986-CB58B129-2C9C-4832-8B07-A680F9580A81Q92965671-94AF77C3-125B-4C84-88B7-DFFECD0AE586
P50
description
Biomedical researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daniel O'Connor
@ast
Daniel O'Connor
@en
Daniel O'Connor
@es
Daniel O'Connor
@nl
type
label
Daniel O'Connor
@ast
Daniel O'Connor
@en
Daniel O'Connor
@es
Daniel O'Connor
@nl
prefLabel
Daniel O'Connor
@ast
Daniel O'Connor
@en
Daniel O'Connor
@es
Daniel O'Connor
@nl
P106
P1153
55630064600
56683157300
P21
P31
P496
0000-0002-6902-9886